Liquidia stock surges 40% on $380.7M litigation settlement with UTHR
Covered in this story
Analyst targets on United Therapeutics
- Goldman Sachs: $472 → $321 by Sep 2027 · Sell via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $UTHR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on United Therapeutics →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.